Over the past 15 years genetic sequencing costs have fallen 100x faster than computing costs. Moore’s law does not keep up.
Today, clinical genetics labs generate terabytes of sequencing data that needs to be analysed and interpreted quickly to diagnose and treat patients efficiently.
Using software, machine learning and decades of experience, we are playing our part in overcoming this challenge.
Making NGS even more valuable
The omnomics Suite gives users of clinical NGS the tools to get the most out of their data. As a package or as individual software products, our tools are helping clinicians to trust their NGS data, find the most important variants for their patient and save time.
Designed with the flexibility to be used for almost any clinical domain running NGS, the omnomics Suite is helping to push the boundaries of what NGS can do for precision medicine.
Genomic regions analysed by users of Euformatics software globally
Clinical NGS industry expected to triple within the decade
The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%. The growth of this market is largely driven by the advancements in and declining costs of NGS platforms and the improving regulatory and reimbursement scenario for NGS-based diagnostic tests.
Grand View Research
Next Generation Sequencing Market Size, Share & Trends Analysis Report, February 2021
Clinical research is expected to be the fastest-growing end-use segment from 2021 to 2028.
Are you our next partner?
We are building a global partner network to help leverage the full benefits of NGS technologies in the clinical environment. If you understand the healthcare market locally and want to include state-of-the-art clinical interpretation and quality control software in your portfolio please reach out to us.
Here are a few examples of our channel partners:
When working with the leading healthcare institutions in the world, we need to ensure that we provide the best-in-class tools for clinical geneticists so that they are able to provide better care for patients. Euformatics products complete our offering from a clinical NGS perspective and together we have delivered many high impact solutions to our customers in North America, Europe and Asia.
Co-Founder and Chief Engineer
We believe that by combining omnomicsQ, the most comprehensive NGS sample quality control tool available on the market, with the analytical power of omnomicsNGS, we can ensure that laboratories running NGS in China produce impactful results, making a real difference to patient lives and the way we treat diseases.
PRESS RELEASE | Euformatics expands into the Chinese NGS market through distribution agreement with INSVAST
The Euformatics offering comes at the right time for the Brazilian market, as NGS takes off and more hospitals and laboratories are looking for the right solution to make their processes simpler. OmnomicsNGS makes variant annotation and reporting easy through its flexible workflows, while omnomicsQ ensures that proper quality control is an integrated part of any NGS lab’s processes.
PRESS RELEASE | Euformatics and Síntese Biotecnologia partner for first sales channel agreement in South America
Abdul Ghani Marwan Elajou
We believe that the omnomics Suite is the best offering on the market for our clinical customers. As the NGS market grows in Saudi Arabia and more laboratories see the value of NGS techniques, we are confident that omnomicsQ will ensure that the quality of the generated data is high while omnomicsNGS will help our medical professionals to quickly annotate and report on dangerous variants.
PRESS RELEASE | Euformatics signs distribution partnership with Illumina distributor for Saudi Arabia, Al Jeel Medical and Trading Company
How we got here – key milestones:
Euformatics is founded
Euformatics is founded by four friends and colleagues, Christophe, Jukka, Jussi and Juha. Experts in software engineering, systems biology, and high-throughput measurements technologies in genomics, they see that the genomics landscape is changing, and that a software tool for helping interpret huge amounts of genomic data will soon be needed.
First product ideas born
What will later become omnomicsNGS is launched in its first iteration in close collaboration with a Finnish hospital.
After a few years in a cold, wooden barracks in Otaniemi, the team move to Keilaniemi near to the Nokia headquarters.
Major new partnership
A milestone partnership with BC Platforms is signed. omnomicsNGS and quality control tool omnomicsQ are sold as BC|Predict and BC|Q on top of BC Platforms genomic data management solution. Customers ask if omnomicsQ could be used for validation; a new idea germinates.
We are profitable!
After 5 years with red numbers, the company reaches its first year of profitability, no longer reliant on external funding. We also make our first appearance at a conference, at ESHG in Glasgow. Our relationship with EMQN starts there and omnomicsV for NGS test validation is launched.
A sign of the quality of the products (literally) – Euformatics partners with global external quality assessors EMQN and UKNEQAS to provide the backbone of the newly created NGS EQA, a relationship that continues to this day.
GEMMA project launches
Euformatics is selected as the analysis software provider for a multi-year international research project that aims to increase our understanding of autism spectrum disorders through studying the role of gut bacteria and the human genome. The project is a multidisciplinary effort that brings together leading pediatric medical research institutions in the US and Europe.
R&D and growth
We spend 60% of our revenue on R&D, and 85% of revenue comes from sales outside of Finland.
COVID & new CEO
The pandemic temporarily brings the world to a standstill. Tommi starts as new CEO with an ambition to grow the company to the next level. The strategy is updated and everyone rallies behind it to deliver.
Back to growth
We worked hard to identify, negotiate and sign new channel partners and customers on all continents and helping the new recruits Tim, Miguel, Iina, Makenzi, Andrey, Benjamin and Rafael get up to speed fast. New offering for pathogen variant surveillance is delivered to the market with funding from Amazon and SYNLAB being the lead customer.
Deepening key partnerships
We focus on building strategic collaboration with selected partners globally to deliver unique value to the clinical NGS space. We are engaging the US market with a significant investment this year to leverage the biggest NGS installed base with our software. We will get our ISO 13485 Quality Management System certificate and implement IVDR compliant NGS workflows together with our customers.
What does the future hold?
As Euformatics reaches the milestone of having more than a dozen customers on each major continent (excluding Antarctica), Tommi makes good on his promise to throw our ever-misbehaving printer out of the window. To be filmed and celebrated by everyone in the company 😊